OvaScience (OVAS) Reaches OvaPrime and OvaTure Goals for 2015; Offers Update

OvaScienceSM (NASDAQ: OVAS) announced the Company has achieved its 2015 corporate goals for the OvaPrime and OvaTure fertility treatments.

• OvaPrime Treatment Preceptorship Program OvaScience commenced a non-commercial preceptorship program with the OvaPrime treatment at an in vitro fertilization (IVF) clinic outside of the United States to gain insight into the clinical efficacy and feasibility of the treatment. The Company expects that physicians using the treatment will report patient experiences by the end of 2016, as clinically meaningful information becomes available.The OvaPrime treatment is a potential fertility treatment that could enable a woman to increase her egg reserve. Approximately 25 percent of women who seek IVF treatment do not make enough or any eggs and therefore are not candidates for IVF. The OvaPrime treatment is designed to transfer a patient’s egg precursor (EggPCSM) cells, immature egg cells found inside the protective ovarian lining, to the patient’s ovaries, where they may mature into fertilizable eggs during a standard IVF process.

• OvaTure Treatment Clinical Development StrategyOvaScience has also defined the process for maturing EggPC cells that is required for OvaTure development. Maturation of EggPC cells to eggs in vitro, or outside the body, would eliminate the need for the hormone hyperstimulation currently required for IVF. The Company’s progress in developing the OvaTure treatment has provided important insights that enabled the treatment to move into clinical translation.The OvaTure treatment is a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections by maturing her EggPC cells into eggs outside the body. It may be an option for women with compromised eggs, who are unable to make eggs or who may be unwilling or unable to undergo hormone hyperstimulation, such as women diagnosed with cancer.

• AUGMENT TreatmentSince its introduction in select international IVF clinics, the AUGMENT treatment has resulted in positive patient experiences for poor prognosis patients, including the births of 22 babies. The clinical experience with the treatment was published in three journals, including a recent review of EggPC cell mitochondria.i, ii, iii The AUGMENT treatment is designed to improve egg health by supplementing a woman’s mature eggs with EggPC cell mitochondria during IVF. The treatment is not available in the U.S.
• Investor DayThe Company has rescheduled its Investor Day to the first half of 2016 and will present at the Oppenheimer 26th Annual Healthcare Conference in December 2015 and at the J.P. Morgan Healthcare Conference in January 2016.

“The promising development of our OvaPrime and OvaTure fertility treatment programs represent new options for women who would like to have their own children but are unable to undergo IVF due to a lack of eggs, as well as those who do not want to endure hormone treatments,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience. “In addition, based on our learnings in 2015, we continue to adapt our commercial operations and infrastructure focused on driving the future commercial success of our AUGMENT treatment. We look forward to providing further details in 2016.”

You May Also Be Interested In

• Roots Corporation to go private in C$4.10-per-share deal with Marquee Brands
• Winnebago Industries extends $350M credit facility to 2031
• Firm Capital Apartment REIT posts Q2 loss, plans name change